OC
NVCR icon

Oppenheimer & Co’s NovoCure NVCR Stock Holding History

Oppenheimer & Co’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,331
Closed -$230K – 1485
2020
Q4 		$230K Buy
+1,331
New +$182K ﹤0.01% 1192
2020
Q3 		– Sell
-4,000
Closed -$237K – 1330
2020
Q2 		$237K Buy
+4,000
New +$263K 0.01% 1054
2019
Q4 		– Sell
-5,852
Closed -$437K – 1301
2019
Q3 		$437K Buy
5,852
+858
+17% +$68.6K 0.01% 837
2019
Q2 		$316K Buy
+4,994
New +$253K 0.01% 985
2018
Q4 		– Sell
-4,000
Closed -$210K – 1328
2018
Q3 		$210K Buy
+4,000
New +$159K 0.01% 1209

Other funds holding NVCR

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Oppenheimer & Co's NVCR Position: Q1 2021 in Review

Oppenheimer & Co sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 1,331 shares — an estimated $230K sold.

Oppenheimer & Co first reported a position in NVCR in Q3 2018 and held it in 5 quarters. The position peaked at $437K in Q3 2019. 327 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

  • Oppenheimer & Co reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
  • Oppenheimer & Co sold 1,331 NovoCure shares in Q1 2021, an estimated $230K.
  • Oppenheimer & Co first reported a position in NovoCure in Q3 2018 and held it in 5 quarters.
  • Oppenheimer & Co's NovoCure position peaked at $437K in Q3 2019.
  • 327 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Oppenheimer & Co's 13F filing for Q1 2021, filed 10 May 2021.